Catalog No.
PHD10101
Species reactivity
Human, Mouse, Rat
Host species
Rabbit
Isotype
IgG
Clonality
Polyclonal
Immunogen
E. coli - derived recombinant Human ACP3 (Leu167-Thr335).
Tested applications
ELISA: 1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000
Target
Prostatic acid phosphatase,Thiamine monophosphatase,ACPP,TMPase,ACP3,Protein tyrosine phosphatase ACP3,5'-nucleotidase,Acid phosphatase 3,PAP,5'-NT,Ecto-5'-nucleotidase
Purification
Purified by antigen affinity column.
Accession
P15309
Applications
ELISA, IHC, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Novel PAP-targeted CAR-T therapy enhances antitumor efficacy through CoupledCAR approach., PMID:40449956
Plant-derived recombinant macromolecular PAP-IgG Fc as a novel prostate cancer vaccine candidate eliciting robust immune responses., PMID:40140219
Race-Related Differences in Sipuleucel-T Response among Men with Metastatic Castrate-Resistant Prostate Cancer., PMID:38856749
Phase 2 trial of a DNA vaccine (pTVG-HP) and nivolumab in patients with castration-sensitive non-metastatic (M0) prostate cancer., PMID:38101860
Co-transient expression of PSA-Fc and PAP-Fc fusion protein in plant as prostate cancer vaccine candidates and immune responses in mice., PMID:37269373
Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials., PMID:37058234
Avelumab in Men With Metastatic Castration-Resistant Prostate Cancer, Enriched for Patients Treated Previously With a Therapeutic Cancer Vaccine., PMID:36821354
Phase 2 trial of T-cell activation using MVI-816 and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC)., PMID:35277461
Biochemical, molecular and cytological impacts of alpha-lipoic acid and Ginkgo biloba in ameliorating testicular dysfunctions induced by silver nanoparticles in rats., PMID:35067888
Targeting the spectrum of immune checkpoints in prostate cancer., PMID:34263692
TGM4: an immunogenic prostate-restricted antigen., PMID:34193566
Prostate Cancer Immunotherapy-Finally in From the Cold?, PMID:34125308
Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer., PMID:33986125
Antibody profiling of patients with prostate cancer reveals differences in antibody signatures among disease stages., PMID:33335027
Long-term Sculpting of the B-cell Repertoire following Cancer Immunotherapy in Patients Treated with Sipuleucel-T., PMID:32967912
Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T., PMID:32145020
Bovine papillomavirus prostate cancer antigen virus-like particle vaccines are efficacious in advanced cancers in the TRAMP mouse spontaneous prostate cancer model., PMID:32016503
Immunohistochemical Reactivity of Prostate-Specific Markers for Salivary Duct Carcinoma., PMID:31865345
Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) using Sipuleucel-T and a DNA vaccine., PMID:29534736
Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment., PMID:28376158
Phase I clinical trial of sipuleucel-T combined with escalating doses of ipilimumab in progressive metastatic castrate-resistant prostate cancer., PMID:28361045
Purification of a Human Prostate Specific Antigen., PMID:28012750
[Preparation and activity validation of PP7 bacteriophage-like particles displaying PAP114-128 peptide]., PMID:27667462
Antitumor vaccination of prostate cancer patients elicits PD-1/PD-L1 regulated antigen-specific immune responses., PMID:27471641
A Magnetic Bead-Based Sensor for the Quantification of Multiple Prostate Cancer Biomarkers., PMID:26421725
Epithelial and stromal alterations in prostate after cypermethrin administration in adult albino rats (histological and biochemical study)., PMID:25987297
Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome., PMID:25649018
Glycoprotein fucosylation is increased in seminal plasma of subfertile men., PMID:25248658
Increased expression of GCNT1 is associated with altered O-glycosylation of PSA, PAP, and MUC1 in human prostate cancers., PMID:24854630
Label-free capacitive diagnostics: exploiting local redox probe state occupancy., PMID:24491045
Beyond sipuleucel-T: immune approaches to treating prostate cancer., PMID:24402184
Antinociceptive effect of prostatic acid phosphatase in a rat model of cancer-induced bone pain., PMID:24284839
Immunodominant semen proteins II: contribution of seminal proteins to female immune infertility., PMID:24280142
The immunohistochemical expression of islet 1 and PAX8 by rectal neuroendocrine tumors should be taken into account in the differential diagnosis of metastatic neuroendocrine tumors of unknown primary origin., PMID:24037217
Simultaneous and combined detection of multiple tumor biomarkers for prostate cancer in human serum by suspension array technology., PMID:23567627
Integration of immunotherapy into the management of advanced prostate cancer., PMID:23040162
The evolving role of immunotherapy in prostate cancer., PMID:22918924
Mass spectrometry-based proteomics as a tool to identify biological matrices in forensic science., PMID:22843116
An artificial PAP gene breaks self-tolerance and promotes tumor regression in the TRAMP model for prostate carcinoma., PMID:22086231
Barcode lateral flow immunochromatographic strip for prostate acid phosphatase determination., PMID:21880451
Exosome targeting of tumor antigens expressed by cancer vaccines can improve antigen immunogenicity and therapeutic efficacy., PMID:21670078
[Alternative tests to PSA for prostate cancer diagnosis]., PMID:21553390
Sipuleucel-T: Prototype for development of anti-tumor vaccines., PMID:21243538
Human cytokine response to Texas crotaline envenomation before and after antivenom administration., PMID:20887908
NKX3.1 as a marker of prostatic origin in metastatic tumors., PMID:20588175
Diagnostic utility of P504S/p63 cocktail, prostate-specific antigen, and prostatic acid phosphatase in verifying prostatic carcinoma involvement in seminal vesicles: a study of 57 cases of radical prostatectomy specimens of pathologic stage pT3b., PMID:20586625
Protein complexes/aggregates as potential cancer biomarkers revealed by a nanoparticle aggregation immunoassay., PMID:20392611
Prostatic acid phosphatase is expressed in peptidergic and nonpeptidergic nociceptive neurons of mice and rats., PMID:20084276
[New drugs in metastatic castration-resistant prostate cancer]., PMID:20022854
Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer., PMID:19636017
For research use only. Not for human or drug use.
